A randomized, double blinded, split-face clinical study of the efficacy of using Eucerin Sun Dry Touch Sebum Control DP to reduce post inflammatory hyperpigmentation after Picosecond laser

Phase 4

• Conditions: mild to moderate acne vulgaris with mild to moderate acne scars; Eucerin Sun Dry Touch Sebum Control DP, Post inflammatory hyperpigmentation, Picosecond laser, Sunscreen, Acne vulgaris

• Registration Number: TCTR20210305004
• Lead Sponsor: Beiersdorf Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-05
• Study Completion: 2021-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. male/female at least 18 years of age
2. mild-moderate acne vulgaris with mild-moderate acne scars
3. Fitz patrick skin phototype 3 or 4
4. able to comply with study protocol
5. willingly inform consent

Exclusion Criteria

1. unable to stop previous treatment (washout period; systemic treatment for acne 3 months, laser/phototherapy 1 month, topical treatment is 2 weeks).
2. having infection or other facial dermatologic conditions at treatment site.
3. Polycystic Ovary Syndrome (PCOS)
4. Pregnant or lactating women
5. allergic to study product.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Post inflammatory hyperpigmentation Wk 0 ,1, 2, 4, 6 Visia (Brown spots)

Secondary Outcome Measures

Name	Time	Method
Acne count Wk 0 ,1, 2, 4, 6 Acne count,Porphyrin Wk 0 ,1, 2, 4, 6 Visia (Porphyrin),Patient satisfaction score Wk 1, 2, 4, 6 Patient satisfaction score (0-10),Acne scars Wk 1, 2, 4, 6 quartile grading scale (evaluated by dermatologist)